JP2007517071A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517071A5
JP2007517071A5 JP2006549289A JP2006549289A JP2007517071A5 JP 2007517071 A5 JP2007517071 A5 JP 2007517071A5 JP 2006549289 A JP2006549289 A JP 2006549289A JP 2006549289 A JP2006549289 A JP 2006549289A JP 2007517071 A5 JP2007517071 A5 JP 2007517071A5
Authority
JP
Japan
Prior art keywords
compound
effective amount
therapeutically effective
acceptable carrier
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006549289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/042070 external-priority patent/WO2005065183A2/en
Publication of JP2007517071A publication Critical patent/JP2007517071A/ja
Publication of JP2007517071A5 publication Critical patent/JP2007517071A5/ja
Withdrawn legal-status Critical Current

Links

JP2006549289A 2003-12-19 2004-12-15 有糸分裂キネシン阻害剤 Withdrawn JP2007517071A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53137203P 2003-12-19 2003-12-19
PCT/US2004/042070 WO2005065183A2 (en) 2003-12-19 2004-12-15 Mitotic kinesin inhibitors

Publications (2)

Publication Number Publication Date
JP2007517071A JP2007517071A (ja) 2007-06-28
JP2007517071A5 true JP2007517071A5 (cg-RX-API-DMAC7.html) 2008-02-21

Family

ID=34748759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006549289A Withdrawn JP2007517071A (ja) 2003-12-19 2004-12-15 有糸分裂キネシン阻害剤

Country Status (7)

Country Link
US (1) US20070060601A1 (cg-RX-API-DMAC7.html)
EP (1) EP1696927A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007517071A (cg-RX-API-DMAC7.html)
CN (1) CN1893951A (cg-RX-API-DMAC7.html)
AU (1) AU2004311737A1 (cg-RX-API-DMAC7.html)
CA (1) CA2549641A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005065183A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536239A (ja) * 2004-05-06 2007-12-13 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
EA200801414A1 (ru) * 2005-11-22 2008-10-30 Смитклайн Бичам Корпорейшн Кальцилитические соединения
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
CN101628913B (zh) * 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
CN107417628A (zh) * 2017-06-28 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 二芳基喹唑啉酮类化合物、其制备方法及其医药用途以及包含该类化合物的药物组合物
CN110041273B (zh) * 2019-05-29 2020-10-20 中国人民解放军军事科学院军事医学研究院 2-(2-氯-4-甲基苯基)喹唑啉-4(3h)-酮类化合物及其医药用途
CN110041272B (zh) * 2019-05-29 2020-10-30 中国人民解放军军事科学院军事医学研究院 2-(2-氯苯基)喹唑啉-4(3h)-酮类衍生物及其制备方法和用途
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
MX2024006627A (es) 2021-12-03 2024-08-22 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257397A (en) * 1963-07-26 1966-06-21 Rexall Drug Chemical Substituted 2, 3-dihydro-4(1h)-quinazolinones
US3231572A (en) * 1963-08-05 1966-01-25 Miles Lab 3-substituted-4-quinazolones
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3463778A (en) * 1967-01-13 1969-08-26 Squibb & Sons Inc Substituted 2,3-dihydro-4(1h)-quinazolinones
DE3166627D1 (en) * 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
DE3717034A1 (de) * 1987-05-21 1988-12-08 Basf Ag Photopolymerisierbare aufzeichnungsmaterialien sowie photoresistschichten und flachdruckplatten auf basis dieser aufzeichnungsmaterialien, sowie neue chinazolon-4-verbindungen
AU7692496A (en) * 1995-11-24 1997-06-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridopyrimidines
US5948775A (en) * 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6479499B1 (en) * 2000-06-28 2002-11-12 National Science Council 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods

Similar Documents

Publication Publication Date Title
JP2008527038A5 (cg-RX-API-DMAC7.html)
Hu et al. Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Haefner NF-κB: arresting a major culprit in cancer
Soares et al. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells
Serafin et al. Drug repositioning in oncology
Abdelaleem et al. Prospects for repurposing CNS drugs for cancer treatment
Jin et al. Curaxin CBL0137 exerts anticancer activity via diverse mechanisms
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
Piperdi et al. Bortezomib: understanding the mechanism of action
ME02048B (me) N-(4-((3-(2-AMINO-4-PIRlMIDlNIL)-2-PIRlDlNlL)OKSI)FENIL)-4-(4-METIL-2-THIENIL)- 1-FTALAZINAMIN ZA PRIMENU U TRETMANU KANCERA REZISTENTNOG NA ANTIMITOTIČKE AGENSE
JP2013504582A5 (cg-RX-API-DMAC7.html)
PT1307197E (pt) Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida
JP2009510171A5 (cg-RX-API-DMAC7.html)
NZ621972A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
McLaughlin et al. Modulation of the opioid growth factor ([Met5]‐enkephalin)–opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck
JP2009539994A5 (cg-RX-API-DMAC7.html)
Eberli et al. Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells
RU2010109452A (ru) Способы и композиции, предназначенные для лечения раковых заболеваний
Srikumar et al. Potential use of flavopiridol in treatment of chronic diseases
Sharma Synthetic and natural compounds as anti-cancer agents–a review
ZA200807323B (en) Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
JP2008527039A5 (cg-RX-API-DMAC7.html)
JP2008527041A5 (cg-RX-API-DMAC7.html)
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
Azrak et al. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells